Healthcare / BiotechnologyTaipei Exchange
$54.90
+0.60 (+1.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $455.3M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.9B
P/E
20.4x
↑EV/EBITDA
12.2x
↑ROE
7.9%
↑Gross Margin
94.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.7%
FCF CAGR
+105.8%
FCF margin
189.4%
FCF / Net income
4.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $911.4M · net income $387.6M · FCF $1.73B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $911.4M | $911.4M | $2.52B | $767.7M | $654.4M |
| Net Income | $387.6M | $387.6M | $1.75B | $274.6M | $318.8M |
| EBITDA | $519.5M | $519.5M | $2.17B | $347.3M | $401.2M |
| EPS | — | — | 12.17 | 1.91 | 2.22 |
| Gross Margin | 94.3% | 94.3% | 98.1% | 93.7% | 92.4% |
| Operating Margin | 46.7% | 46.7% | 81.4% | 36.1% | 43.2% |
| Net Margin | 42.5% | 42.5% | 69.4% | 35.8% | 48.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 27.17 | 27.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.73B | $1.73B | $455.3M | $256.6M | $198.1M |
| Returns | |||||
| ROE | 7.9% | 7.9% | 32.4% | 7.1% | 8.2% |
| Valuation | |||||
| P/E | 20.41 | 20.41 | 8.08 | 57.07 | 56.53 |
| EV/EBITDA | 12.22 | 12.22 | 6.06 | 42.63 | 40.60 |
| P/B | 1.60 | 1.60 | 2.62 | 4.06 | 4.66 |
| Growth & Yield | |||||
| Revenue Growth | -63.9% | -63.9% | 228.7% | 17.3% | — |
| EPS Growth | — | — | 537.2% | -14.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.6%
Start / end P/E
n/dx → n/dx
EPS bridge
12.17 → n/d
Residual
-40.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.